The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

Described herein are compositions and methods for the efficient production of a heteromultimeric antibodies, such as a bispecific antibodies. The compositions and methods improve assembly of the heteromultimeric antibodies at higher yield and efficiency than conventional methods. Antibodies are optionally fused with a cytokine or costimulatory peptide or portions thereof. Also described herein are monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecific antibodies thereof that specifically bind CD3. Described herein are methods of making and using the anti-CD3 antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

The present disclosure provides CD19 binding molecules that specifically bind to CD19 including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.